Standard BioTools Inc.

NasdaqGM:SLGC Stock Report

Market Cap: US$396.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Standard BioTools Valuation

Is SLGC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of SLGC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate SLGC's fair value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate SLGC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SLGC?

Key metric: As SLGC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SLGC. This is calculated by dividing SLGC's market cap by their current revenue.
What is SLGC's PS Ratio?
PS Ratio4.8x
SalesUS$81.72m
Market CapUS$396.23m

Price to Sales Ratio vs Peers

How does SLGC's PS Ratio compare to its peers?

The above table shows the PS ratio for SLGC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
NAGE Niagen Bioscience
4x17.43%US$495.8m
QTRX Quanterix
2.5x13.97%US$345.7m
PSNL Personalis
12.1x18.33%US$878.3m
CYRX Cryoport
2.2x1.89%US$552.3m
SLGC Standard BioTools
4.8x16.43%US$396.2m

Price-To-Sales vs Peers: SLGC is expensive based on its Price-To-Sales Ratio (4.8x) compared to the peer average (2.7x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does SLGC's PS Ratio compare vs other companies in the US Life Sciences Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.5x2.62%US$1.52b
ATLN Atlantic International
0.4x7.04%US$152.75m
SNCE Science 37 Holdings
0.6x17.47%US$34.67m
HBIO Harvard Bioscience
0.3x5.14%US$26.18m
SLGC 4.8xIndustry Avg. 3.6xNo. of Companies9PS02.44.87.29.612+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SLGC is expensive based on its Price-To-Sales Ratio (4.8x) compared to the US Life Sciences industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is SLGC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SLGC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.8x
Fair PS Ratio1.6x

Price-To-Sales vs Fair Ratio: SLGC is expensive based on its Price-To-Sales Ratio (4.8x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SLGC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Jan ’27n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Dec ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Nov ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Oct ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Sep ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Aug ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Jul ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Jun ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
May ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Apr ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Mar ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Feb ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Jan ’26n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Dec ’25n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Nov ’25n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Oct ’25n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Sep ’25n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Aug ’25n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Jul ’25n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Jun ’25n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
May ’25n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Apr ’25n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Mar ’25n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Feb ’25n/a
US$3.93
0%
55.17%US$7.00US$2.30n/a3
Jan ’25US$2.53
US$3.93
+55.47%
55.17%US$7.00US$2.30n/a3
US$3.93
Fair Value
46.6% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/09 12:18
End of Day Share Price 2024/01/05 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Standard BioTools Inc. is covered by 3 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle MiksonCanaccord Genuity
Brandon CouillardJefferies LLC
Daniel BrennanTD Cowen